Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cartesian Therapeutics

15.80
-0.8100-4.88%
Post-market: 15.800.00000.00%17:24 EDT
Volume:198.17K
Turnover:3.21M
Market Cap:406.46M
PE:-0.68
High:16.75
Open:16.58
Low:15.80
Close:16.61
Loading ...

Cartesian Therapeutics initiated with a Buy at BTIG

TipRanks
·
20 Dec 2024

BTIG Research Initiates Coverage on Cartesian Therapeutics With Buy Rating, $42 Price Target

MT Newswires Live
·
19 Dec 2024

Cartesian Therapeutics Files for Proposed Resale or Other Disposition by Selling Stockholders of up to 6.3 Mln Common Stock - SEC Filing

THOMSON REUTERS
·
14 Dec 2024

Cartesian Therapeutics files $400M mixed securities shelf

TIPRANKS
·
14 Dec 2024

Cartesian Therapeutics : Sales Agreement Prospectus Covers Offering of up to $100 Mln Common Stock That May Be Issued From Time to Time

THOMSON REUTERS
·
14 Dec 2024

Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), Cartesian Therapeutics (RNAC) and Terns Pharmaceuticals (TERN)

TIPRANKS
·
06 Dec 2024

Promising Clinical Developments and Pivotal Trials Position Cartesian Therapeutics for Long-term Success

TIPRANKS
·
06 Dec 2024

Cartesian Therapeutics Price Target Raised to $45.00/Share From $41.00 by HC Wainwright & Co.

Dow Jones
·
04 Dec 2024

Cartesian Therapeutics price target raised to $45 from $41 at H.C. Wainwright

TIPRANKS
·
04 Dec 2024

Cartesian Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $45 From $41

THOMSON REUTERS
·
04 Dec 2024

Cartesian Therapeutics Reports Promising Phase 2b Trial Results

TIPRANKS
·
03 Dec 2024

Cartesian Therapeutics reports positive updated Phase 2b results in myasthenia

TIPRANKS
·
03 Dec 2024

Cartesian Therapeutics Announces Positive Updated Results From Phase 2B Trial of Descartes-08 in Participants With Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial

THOMSON REUTERS
·
03 Dec 2024

Cartesian Therapeutics Inc - Phase 2B Trial Shows 5.5-Point Reduction in Mg-Adl at Month 4

THOMSON REUTERS
·
03 Dec 2024

Cartesian Therapeutics Inc - Phase 3 Aurora Trial to Commence in 1H2025

THOMSON REUTERS
·
03 Dec 2024

Cartesian Therapeutics Inc -Safety Profile Consistent With Previously Reported Data and Continues to Support Outpatient Administration

THOMSON REUTERS
·
03 Dec 2024